Citations

Showing 10 of 108119 citations.

Molecular and Clinical Characterization of Postpartum-Associated Breast Cancer in the Carolina Breast Cancer Study Phase I–III, 1993–2013
Vohra, Sanah , Walens, Andrea , Schedin, Pepper , Nichols, Hazel B. , Reeder‐Hayes, Katherine E. , Love, Michael I. , Vohra, Sanah N , Schedin, Pepper , Nichols, Hazel B , Love, Michael I , Hamilton, Alina M. , Sherman, Mark E. , Olshan, Andrew F. , Troester, Melissa A.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 22, 2021 | Volume: 31 | Issue: 3 | Pages: 561-568

10.1158/1055-9965.epi-21-0940 | PMID 34810211 Get It

Abstract Background: Breast cancers in recently postpartum women may have worse outcomes, but studies examining tumor molecular features by pregnancy recency have shown conflicting results. Methods: This analysis used Carolina Breast Cancer Study data to examine clinical and molecular tumor features among women less than 50 years of age who were recently (≤10 years prior) or remotely (>10 years prior) postpartum, or nulliparous. Prevalence odds ratios (POR) and 95% confidence intervals (CI) were estimated using multivariable models. Results: Recently postpartum women (N = 618) were more frequently lymph node–positive [POR (95% CI): 1.66 (1.26–2.19)], estrogen receptor (ER)-negative [1.37 (1.02–1.83)], and IHC-based triple negative [1.57 (1.00–2.47)] compared with nulliparous (N = 360) women. Some differences were identified between recent versus remotely postpartum; smaller tumor size [0.67 (0.52–0.86)], p53 wildtype [0.53 (0.36–0.77)], and non–basal-like phenotype [0.53 (0.33–0.84)] were more common among recently postpartum. Recently postpartum (vs. nulliparous) had significant enrichment for adaptive immunity, T cells, B cells, CD8 T cells, activated CD8 T cells/natural killer (NK) cells, and T follicular helper (Tfh) cells and higher overall immune cell scores. These differences were attenuated in remotely (compared with recently) postpartum women. Conclusions: These results suggest a dominant effect of parity (vs. nulliparity) and a lesser effect of pregnancy recency on tumor molecular features, although tumor immune microenvironments were altered in association with pregnancy recency. Impact: Our study is unique in examining tumor immune microenvironment and RNA-based markers according to time since last childbirth. Future studies should examine the interplay between tumor features, postdiagnostic treatment, and outcomes among recently postpartum women. See related commentary by McDonald et al., p. 518
Physician Responsibility to Discuss Palliative Unproven Therapies With Out-of-Option Patients
Kawam, Omar , Tilburt, Jon C. , Master, Zubin , Master, Zubin

Mayo Clinic

The American Journal of Bioethics | November 22, 2021 | Volume: 21 | Issue: 12 | Pages: 31-33

10.1080/15265161.2021.1991038 | PMID 34806967 Get It

Association of Preoperative Opioid Use With Complication Rates and Resource Use in Patients Undergoing Hip Arthroscopy for Femoroacetabular Impingement
Wilson, Jacob M. , Schwartz, Andrew , Xerogeanes, John W. , Nazzal, Ehab M. , Farley, Kevin X.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | November 22, 2021 | Volume: 9 | Issue: 11 | Pages: No page available

10.1177/23259671211045954 | PMID 34881336 Get It

Background: Preoperative opioid use has been shown to be a negative predictor of patient outcomes, complication rates, and resource utilization in a variety of different orthopaedic procedures. To date, there are no studies investigating its effect on outcomes after hip arthroscopy in the setting of femoroacetabular impingement (FAI). Purpose: To determine the association of preoperative opioid use with postoperative outcomes after hip arthroscopy in patients with FAI. Study Design: Cohort study; Level of evidence, 3. Methods: The Truven Health MarketScan Commercial Claims and Encounters Database was queried for all patients who underwent hip arthroscopy for FAI between 2011 and 2018. Opioid prescriptions filled in the 6 months preceding surgery were queried, and the average daily oral morphine equivalents (OMEs) in this period were computed for each patient. Patients were divided into 4 cohorts: opioid naïve, <1 OME per day, 1 to 5 OMEs per day, and >5 OMEs per day. Postoperative 90-day complications, health care utilization, perioperative costs, postoperative opioid use, and 1- and 3-year revision rates were then compared among cohorts. Results: A total of 22,124 patients were ultimately included in this study; 31.2% of these patients were prescribed opioids preoperatively. Overall, the percentage of preoperative opioid-naïve patients increased from 64.5% in 2011 to 78.9% in 2018. Patients who received preoperative opioids had a higher rate of complications, increased resource utilization, and increased revision rates. Specifically, on multivariate analysis, patients taking >5 OMEs per day (compared with patients who were preoperatively opioid naïve) had increased odds of a postoperative emergency department visit (Odds Ratio, 2.23; 95% confidence interval [CI], 1.94-2.56; P < .001), 90-day readmission (OR, 2.25; 95% CI, 1.77-2.87; P < .001), increased acute postoperative opioid use (OR, 25.56; 95% CI, 22.98-28.43; P < .001), prolonged opioid use (OR, 10.45; 95% CI, 8.92-12.25; P < .001), and 3-year revision surgery (OR, 2.14; 95% CI, 1.36-3.36; P < .001). Perioperative adjusted costs were increased for all preoperative opioid users and were highest for the >5 OMEs per day cohort ($6255; 95% CI, $5143-$7368). Conclusion: A large number of patients with FAI are prescribed opioids before undergoing hip arthroscopy, and use of these pain medications is associated with increased health care utilization, increased costs, prolonged opioid use, and early revision surgery.
Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
Kanakkanthara, Arun , Hou, Xiaonan , Ekstrom, Thomas L. , Zanfagnin, Valentina , Huehls, Amelia M. , Kelly, Rebecca L. , Ding, Husheng, Vasmatzis, George , Oberg, Ann L. , Weroha, S. John , Karnitz, Larry M., Oberg, Ann L , Kaufmann, Scott H , Mansfield, Aaron S , Larson, Melissa C. , Kaufmann, Scott H. , Mansfield, Aaron S.

Mayo Clinic

Cancer Research | November 22, 2021 | Volume: 82 | Issue: 2 | Pages: 307-319

10.1158/0008-5472.can-21-0732 | PMID 34810199 Get It

Abstract PARP inhibitors (PARPi) have activity in homologous recombination (HR) repair-deficient, high-grade serous ovarian cancers (HGSOC). However, even responsive tumors develop PARPi resistance, highlighting the need to delay or prevent the appearance of PARPi resistance. Here, we showed that the ALK kinase inhibitor ceritinib synergizes with PARPis by inhibiting complex I of the mitochondrial electron transport chain, which increases production of reactive oxygen species (ROS) and subsequent induction of oxidative DNA damage that is repaired in a PARP-dependent manner. In addition, combined treatment with ceritinib and PARPi synergized in HGSOC cell lines irrespective of HR status, and a combination of ceritinib with the PARPi olaparib induced tumor regression more effectively than olaparib alone in HGSOC patient-derived xenograft (PDX) models. Notably, the ceritinib and olaparib combination was most effective in PDX models with preexisting PARPi sensitivity and was well tolerated. These findings unveil suppression of mitochondrial respiration, accumulation of ROS, and subsequent induction of DNA damage as novel effects of ceritinib. They also suggest that the ceritinib and PARPi combination warrants further investigation as a means to enhance PARPi activity in HGSOC, particularly in tumors with preexisting HR defects. Significance: The kinase inhibitor ceritinib synergizes with PARPi to induce tumor regression in ovarian cancer models, suggesting that ceritinib combined with PARPi may be an effective strategy for treating ovarian cancer.
Cholangiocarcinoma: what are the most valuable therapeutic targets – cancer-associated fibroblasts, immune cells, or beyond T cells?
Loeuillard, Emilien , Wang, Juan , Gores, Gregory J. , Ilyas, Sumera I.

Mayo Clinic

Expert Opinion on Therapeutic Targets | November 22, 2021 | Volume: 25 | Issue: 10 | Pages: 835-845

10.1080/14728222.2021.2010046 | PMID 34806500 Get It

SARS–CoV‐2 Infection and COVID‐19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta‐Analysis
Conway, Richard , Grimshaw, Alyssa , Konig, Maximilian F. , Putman, Michael , Duarte‐García, Alí , Tseng, Leslie Yingzhijie , Cabrera, Diego M. , Chock, Yu Pei Eugenia, Degirmenci, Huseyin Berk , Duff, Eimear , Egeli, Buğra Han , Gupta, Akash , Hoyer, Bimba F. , Jayatilleke, Arundathi , Jin, Shangyi , Kasia, Christopher , Khilnani, Aneka , Kilian, Adam , Kim, Alfred H.J. , Lin, Chung Mun Alice , Low, Candice , Sparks, Jeffrey A. , Tam, Herman , Ugarte‐Gil, Manuel F. , Ung, Natasha, Wang, Kaicheng , Wise, Leanna , Yang, Ziyi , Young, Kristen , Grainger, Rebecca , Wallace, Zachary S. , Hsieh, Evelyn , Alliance, the COVID‐19 Global Rheumatology, Grimshaw, Alyssa A , Graef, Elizabeth R , Hoyer, Bimba F , Jayatilleke, Arundathi , Kilian, Adam , Kim, Alfred H J , Lin, Chung Mun Alice , Proulx, Laurie , Sattui, Sebastian E , Singh, Namrata , Sparks, Jeffrey A , Ugarte-Gil, Manuel F , Wang, Kaicheng , Wise, Leanna M , Young, Kristen J , Liew, Jean , Grainger, Rebecca , Wallace, Zachary S , Hsieh, Evelyn , Duarte-García, Alí , Conway, Richard , Graef, Elizabeth R. , Harkins, Patricia , Sattui, Sebastian E. , Liew, Jean W. , Alliance, the COVID‐19 Global Rheumatology

Mayo Clinic

Arthritis & Rheumatology | November 22, 2021 | Volume: 74 | Issue: 5 | Pages: 766-775

10.1002/art.42030 | PMID 34807517 Get It

ObjectiveThe relative risk of SARS–CoV‐2 infection and COVID‐19 disease severity among people with rheumatic and musculoskeletal diseases (RMDs) compared to those without RMDs is unclear. This study was undertaken to quantify the risk of SARS–CoV‐2 infection in those with RMDs and describe clinical outcomes of COVID‐19 in these patients.MethodsWe conducted a systematic literature review using 14 databases from January 1, 2019 to February 13, 2021. We included observational studies and experimental trials in RMD patients that described comparative rates of SARS–CoV‐2 infection, hospitalization, oxygen supplementation/intensive care unit (ICU) admission/mechanical ventilation, or death attributed to COVID‐19. Methodologic quality was evaluated using the Joanna Briggs Institute critical appraisal tools or the Newcastle‐Ottawa scale. Risk ratios (RRs) and odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated, as applicable for each outcome, using the Mantel‐Haenszel formula with random effects models.ResultsOf the 5,799 abstracts screened, 100 studies met the criteria for inclusion in the systematic review, and 54 of 100 had a low risk of bias. Among the studies included in the meta‐analyses, we identified an increased prevalence of SARS–CoV‐2 infection in patients with an RMD (RR 1.53 [95% CI 1.16–2.01]) compared to the general population. The odds of hospitalization, ICU admission, and mechanical ventilation were similar in patients with and those without an RMD, whereas the mortality rate was increased in patients with RMDs (OR 1.74 [95% CI 1.08–2.80]). In a smaller number of studies, the adjusted risk of outcomes related to COVID‐19 was assessed, and the results varied; some studies demonstrated an increased risk while other studies showed no difference in risk in patients with an RMD compared to those without an RMD.ConclusionPatients with RMDs have higher rates of SARS–CoV‐2 infection and an increased mortality rate.
Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm
Gangat, Naseema , Konopleva, Marina , Patnaik, Mrinal M. , Jabbour, Elias , DiNardo, Courtney D. , Al‐Kali, Aref , Foran, James M. , Granroth, Ginna L., Olteanu, Horatiu , Kadia, Tapan M. , Tefferi, Ayalew , Pemmaraju, Naveen , DiNardo, Courtney , Kadia, Tapan M , Jabbour, Elias , Granroth, Ginna

Mayo Clinic

American Journal of Hematology | November 22, 2021 | Volume: 97 | Issue: 2 | Pages: No page available

10.1002/ajh.26417 | PMID 34807470 Get It

Epidemiology of Uveitis in Olmsted County, Minnesota: A Population-Based Follow-Up Study
Xu, Timothy T. , Hodge, David O. , Smith, Wendy M. , Reynolds, Margaret

Mayo Clinic

Ocular Immunology and Inflammation | November 22, 2021 | Volume: 31 | Issue: 1 | Pages: 112-118

10.1080/09273948.2021.1988113 | PMID 34802369 Get It

Avoiding Retained Surgical Items at an Academic Medical Center: Sustainability of a Surgical Quality Improvement Project
Bearden, Brenda A, Kollengode, Anantha, Nienow, Joseph M., Weisbrod, Cheryl A., Dowdy, Sean C. , Amstutz, Gwendolyn J., Narr, Bradly J., Cima, Robert R. , Bearden, Brenda A

Mayo Clinic

American Journal of Medical Quality | November 22, 2021 | Volume: 37 | Issue: 3 | Pages: 236-245

10.1097/jmq.0000000000000030 | PMID 34803134 Get It

Unintentionally retained surgical items (RSIs) are a serious complication representing a surgical “Never” event. The authors previously reported the process and significant improvement over a 3-year multiphased quality improvement RSI reduction effort that included sponge-counting technology. Herein, they report the sustainability of that effort over the decade following the formal quality improvement project conclusion. This retrospective analysis includes descriptive and qualitative data collected during RSI event root cause analysis. Between January 2009 and December 2019, 640 889 operations were performed with 24 RSIs reported. The resulting RSI rate of 1 per 26 704 operations represent a 486% performance improvement compared to the preintervention rate of 1 per 5500 operations. The interval, in days, between RSI events increased to 160 from 26 during the preintervention phase. Cotton sponges were the most retained RSI despite the use of sponge-counting technology. A significant and sustained reduction in RSI is possible after designing a sustainable comprehensive multidisciplinary effort.